| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.parmaxpharma.com | |
| Market Cap | 11.04 Cr. | |
| Enterprise Value(EV) | 16.57 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.86 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 31.87 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 11.17 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 2.64 | Calculated using Price: 29.50 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 0.37 Cr. | 3,741,300 Shares |
| FaceValue | 10 | |
| About Parmax Pharma Ltd. | ||
| Parmax Pharma was incorporated on November 02, 1994. The certificate of commencement of business was received by the company on March 10, 1995.The IPO of the company was January 30, 1996 with 5100800 shares of Rs10/-each. The promoters were earlier in manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The company then discontinued its business activities for few years due to various reasons. The company also plans to extend its activity in formulation of Tablets, Capsules, Ointments, & Injectable. | ||
| 1 Day |
|
|
| 1 Week |
|
+0.24% |
| 1 Month |
|
-10.06% |
| 3 Month |
|
-10.33% |
| 6 Month |
|
-17.83% |
| 1 Year |
|
-24.74% |
| 2 Year |
|
-49.23% |
| 5 Year |
|
+52.85% |
| 10 Year |
|
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 1.16 | 0.70 | -0.12 | -0.28 | 0.02 | 3.71 | 18.19 | 22.55 | 3.38 | |
| Return on Capital Employed (%) | 1.01 | 0.88 | 0.28 | 0.18 | 0.81 | 1.96 | 10.19 | 16.25 | 6.62 | |
| Return on Assets (%) | 0.73 | 0.45 | -0.08 | -0.12 | 0.00 | 0.43 | 2.11 | 3.45 | 0.70 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 4 | |
| Non Curr. Liab. | 1 | 1 | 0 | 1 | 2 | 5 | 5 | 6 | 5 | 6 | |
| Curr. Liab. | 0 | 0 | 0 | 2 | 10 | 10 | 11 | 11 | 7 | 6 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 5 | 5 | 5 | 8 | 17 | 20 | 21 | 23 | 18 | 16 | |
| Non Curr. Assets | 3 | 3 | 3 | 3 | 6 | 9 | 10 | 11 | 11 | 11 | |
| Curr. Assets | 2 | 2 | 2 | 4 | 9 | 9 | 9 | 10 | 7 | 5 | |
| Misc. Exp. not W/O | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | ||
| Total Assets | 5 | 5 | 5 | 8 | 17 | 20 | 21 | 23 | 18 | 16 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 12 | 12 | 21 | 26 | 18 | 16 | |||||
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 0 | 0 | 0 | 0 | 12 | 12 | 21 | 26 | 18 | 16 | |
| Total Expenditure | 0 | 0 | 0 | 0 | -11 | -11 | -19 | -23 | -16 | -14 | |
| PBIDT | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 3 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Depreciation | -1 | -1 | -1 | -2 | -2 | -2 | |||||
| Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Exceptional Items | |||||||||||
| PAT | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |||
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | -1 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | -1 | 4 | 1 | 3 | 4 | 1 | ||
| Cash Fr. Inv. | 0 | -4 | -3 | -2 | -3 | -2 | |||||
| Cash Fr. Finan. | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 0 | -1 | ||
| Net Change | 0 | 0 | 0 | 1 | 1 | 0 | 1 | -2 | |||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 1 |
|
Tue, 23 May 2023
Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. |
|||||||||||||||||||||
|
Wed, 10 May 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. |
|||||||||||||||||||||
|
Sat, 29 Apr 2023
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: YASH VORA Designation: COMPANY SECRETARY EmailId: CS@PARMAXPHARMA.COM Name of the Chief Financial Officer: KEYUR VORA Designation: CHIEF FINANCIAL OFFICER EmailId: KEYURVORA@PARMAXPHARMA.COM Date: 29/04/2023 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
| Fri, 26 May 2023 |
Opening at High
|
Close Within 52 Week Low Zone
|
Close Entering 52 Week Low Zone
|
High Decrease in 3 Months
|
CCI Crossed Below -100
|
Equities
M.F.
Sectors
StockEdge Social